Atopic Dermatitis

FDA clears lebrikizumab (EBGLYSS) every-8-week maintenance dosing for moderate to severe atopic dermatitis, reducing maintenance injections to as few as 6 per year.

Lakshi M. Aldredge, MSN, ANP-BC, DCNP, discusses late-breaking data preseneted at SDNP on novel immune-mediated therapies for atopic dermatitis, alopecia areata, and hidradenitis suppurativa.

Jared Gollob, MD, discusses phase 1b biomarker findings for KT-621, a STAT6 degrader in atopic dermatitis, presented at SID 2026.

Unlike approved AD biologics and JAK inhibitors targeting specific cytokine pathways, GX-03 is designed to modulate inflammatory signaling locally within the skin microenvironment.

Albert Chiou, MD, MBA, reviews updates presented at SID 2026 on phase 1 data showing soquelitinib activity in prior systemic therapy failures, with a well-balanced adverse event profile vs placebo.

Apogee plans to initiate 3 phase 3 trials of zumilokibart in moderate to severe atopic dermatitis—ADventure 1, ADventure 2, and ADventure TCS—in the second half of 2026.

Among more than 1700 patients enrolled in the long-term extension study, the majority transitioned from a moderate to severe AD phenotype at baseline to a mild phenotype within 12 weeks, with that shift maintained through 2 years.

Phase 3 data presented at AAD 2026 showed that amlitelimab significantly improved skin clearance and disease severity in patients aged 12 years and older with moderate to severe atopic dermatitis.

Matthew Zirwas, MD, rethinks AD as environmentally acquired barrier dysfunction, sharing psychodermatology itch strategies and highlighting patient-centered communication.

Albert Chiou, MD, MBA, discusses results from the phase 1 trial of soquelitinib for moderate to severe AD presented at SID 2026.

The patented filaggrin-targeting regimen claims up to 99% atopic dermatitis relief without steroids, boosting hydration and calming itch in adults.

Treatment discontinuations due to laboratory abnormalities were uncommon, occurring in 0.7% of patients at week 52 and remaining below 2% through week 140.

Biologics and oral JAK inhibitors are now strongly recommended for moderate to severe pediatric atopic dermatitis, signaling a shift toward earlier systemic treatment escalation.

Emma Guttman-Yassky, MD, PhD, discusses findings from an abrocitinib on-off JADE REGIMEN analysis and what they may mean for disease modification in atopic dermatitis.

Dermatology Times' editor in chief highlights essential late-breakers from AAD 2026, including rademikibart, KT-621, nemolizumab, and delgocitinib.

Data show that upadacitinib reduces systemic inflammatory burden in AD, including hs-CRP, a biomarker validated as an independent predictor of major cardiovascular events.

In this episode, Renata Block, DMSc, MMS, PA-C, and Zachary Rubin, MD, discuss the overlapping worlds of allergy and dermatology—and how better cross-specialty understanding can dramatically improve patient outcomes.

A 24-week trial shows ruxolitinib cream sustains control and itch relief in moderate atopic dermatitis when steroids fail, with a positive safety profile.

Once-daily roflumilast cream brings fast itch relief, EASI-75 responses, and reassuring safety in 3–24 months, supporting a recent sNDA to the FDA.

Allergist and bestselling author Zachary Rubin, MD, joins host Renata Block, DMSc, MMS, PA-C, to debunk common allergy and atopic dermatitis myths and explore the immunology of the atopic march, cross-specialty collaboration, and more.

New research shows podiatry students struggle to spot psoriasis and eczema on darker skin, exposing dermatology training gaps and driving calls for inclusive teaching.

FDA will review a supplemental New Drug Application for topical roflumilast to treat infant AD with supporting trial data showing rapid itch relief and clear skin gains from week 1.

Gain exclusive insights from AAD on rapid-onset topicals, durable biologic control, and a growing emphasis on stringent, patient-centered targets shaping atopic dermatitis care.

Early clinical trials indicate that dual- and triple-target antibodies may provide faster onset and more consistent itch relief in moderate to severe AD.

Clinicians agreed that itch — not lesion count or BSA alone — is the most clinically meaningful driver of treatment escalation in patients with atopic dermatitis.